Connect Biopharma (NASDAQ: CNTB) executives report share purchases

Rhea-AI Filing Summary

Connect Biopharma Holdings Limited filed a current report describing open-market share purchases by two senior executives over the past year. Chief Executive Officer Barry D. Quart, Pharm.D., bought a total of 224,034 company shares in multiple transactions between September 2024 and September 2025. President David Szekeres purchased a total of 215,739 shares in transactions occurring between November 2024 and September 2025. The company states that all of these purchases complied with its Insider Trading Compliance Policy and characterizes this information as furnished under Regulation FD, not filed for liability purposes.

0001835268false00018352682025-09-162025-09-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________________

FORM 8-K

________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 16, 2025

________________________________________

Connect Biopharma Holdings Limited

(Exact name of Registrant as Specified in Its Charter)

________________________________________

Cayman Islands			001-40212			Not Applicable
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
			3580 Carmel Mountain Road, Suite 200
			San Diego, California			92130
			(Address of Principal Executive Offices)			(Zip Code)

Registrant’s Telephone Number, Including Area Code: (877) 245-2787

________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Ordinary Shares, par value $0.000174 per share

CNTB

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 7.01 Regulation FD Disclosure.

Barry D. Quart, Pharm.D., Chief Executive Officer and Director of Connect Biopharma Holdings Limited (the “Company”), purchased a total of 224,034 shares of the Company in a series of transactions occurring between September 2024 and September 2025.

David Szekeres, President of the Company, purchased a total of 215,739 shares of the Company in a series of transactions occurring between November 2024 and September 2025.

All purchases described in this Item 7.01 were made in compliance with the Company’s Insider Trading Compliance Policy, as in effect at the applicable times.

The information in Item 7.01 of this Current Report on Form 8-K is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Except as required by law, the Company undertakes no obligation to publicly update any information furnished in this Item 7.01, whether because of future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									CONNECT BIOPHARMA HOLDINGS LIMITED
Date:			September 16, 2025			By:			/s/ David Szekeres
						Name:			David Szekeres
						Title:			President

FAQ

What did Connect Biopharma (CNTB) disclose in this 8-K filing?

Connect Biopharma disclosed that two senior executives bought company shares in the open market over several months, and that these purchases complied with the company’s Insider Trading Compliance Policy.

How many Connect Biopharma shares did the CEO purchase?

Chief Executive Officer Barry D. Quart, Pharm.D., purchased a total of 224,034 shares of Connect Biopharma in a series of transactions between September 2024 and September 2025.

How many Connect Biopharma shares did the President purchase?

President David Szekeres purchased a total of 215,739 shares of Connect Biopharma in a series of transactions between November 2024 and September 2025.

Over what period did these Connect Biopharma insider purchases occur?

The CEO’s share purchases occurred between September 2024 and September 2025, while the President’s purchases occurred between November 2024 and September 2025.

Were the Connect Biopharma insider share purchases compliant with company policies?

Yes. The company states that all purchases described were made in compliance with its Insider Trading Compliance Policy, as in effect at the applicable times.

Is the insider purchase information considered filed or furnished for Exchange Act purposes?

The information is being furnished under Item 7.01 of Regulation FD and is expressly stated as not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934.